Group 1: Yanjing Beer (000729) - Company Deep Report - Strong growth momentum, overcoming low profitability issues. Revenue is expected to grow at a CAGR of 5.04% from 2019 to 2024, while net profit attributable to shareholders is projected to grow at a CAGR of 35.64% during the same period [5] - Cost improvements through production and sales separation have led to a 6.62 percentage point increase in capacity utilization to 46.86% from 2019 to 2024, and a 1.59 percentage point decrease in depreciation and amortization as a percentage of revenue to 4.64% [5] - The effective tax rate is expected to decrease by 18.38 percentage points to 15.78% from 2021 to 2024, contributing to an increase in profitability, with the net profit margin projected to reach 7.20% in 2024, up 2.66 percentage points year-on-year [5] Group 2: Yanjing Beer - Market Dynamics - The main consumer demographic for beer is aged 18-49, with beer production stabilizing since 2021 after a decline. The beer industry is expected to see a slight increase in production from 2025 to 2030, with a CAGR of 0.17% in the main consumer group [6] - The beer industry is highly concentrated, with the top five companies holding over 90% market share. The CR5 is projected to reach 90.73% in 2024, indicating limited potential for further concentration, with price increases being the primary driver for performance growth [6] Group 3: Yanjing Beer - Growth Path - The company plans to expand the U8 product line to create a second national flagship product, aiming to enhance the scale and lifecycle of U8 while increasing its market penetration [7] - The company is focusing on underdeveloped markets through initiatives like the "Hundred Counties, Hundred Cities" project, aiming to improve sales efficiency in key regions [7] - Aiming to enhance factory efficiency and reduce costs, the company is implementing a management system with quantifiable metrics and standards, which is expected to improve capacity utilization and profitability [7] Group 4: Collagen Industry - Deep Report - Collagen is a vital component in the human body, providing strength and support to various tissues. It has low immunogenicity and is biodegradable, making it essential for numerous biological functions [10] - Domestic recombinant collagen technology is leading globally, with a complete industrial chain from raw material development to end application, supported by favorable government policies [10][11] - The market for recombinant collagen is expected to grow at a CAGR of 41.4% from 2023 to 2027, surpassing the growth of animal-derived collagen, which is projected at 27.7% [11] Group 5: Collagen Industry - Applications and Market Potential - The light medical beauty market is expanding, with recombinant collagen expected to grow from 4.3 billion yuan in 2023 to 14.3 billion yuan by 2027, a CAGR of 35.4% [12] - In skincare, the market for functional skincare products is projected to grow from 11.5 billion yuan in 2023 to 66.5 billion yuan by 2027, with a CAGR of 54.9% [12] - The private health sector is seeing innovations with recombinant collagen products, such as vaginal dressings, which address specific health issues [12] Group 6: Investment Recommendations - The domestic beauty care market is rapidly evolving, with increasing consumer acceptance of new products and a focus on efficacy and core ingredients. The collagen market is expected to expand significantly [13]

Core Insights - The functional skincare industry in China is experiencing a rise of domestic brands, with a focus on products that address specific skin issues and provide therapeutic benefits [1][8] - The market size for functional skincare products is projected to exceed 480 billion yuan by 2024, driven by increasing consumer demand for safety and efficacy [25][31] Industry Overview - Functional skincare products are defined as cosmetics or medical devices that target specific skin problems and possess pharmacological effects [1] - The industry is currently in a phase of domestic brand emergence, with significant growth in market share for local brands like Winona and Huaxi Biological [8] Industry Chain Analysis - The functional skincare industry chain consists of upstream raw material suppliers, midstream manufacturers, and downstream sales channels [4][6] - Key raw materials include collagen, hyaluronic acid, and peptides, while packaging materials range from paper to glass [4] Market Development History - The industry has gone through three stages: initiation (1998-2008), transformation (2009-2014), and the current rise of domestic brands (2015-present) [8] - The entry of brands like Vichy and Avene marked the beginning of the functional skincare market in China [8] Policy Background - The industry is governed by regulations applicable to both cosmetics and medical devices, focusing on efficacy claims and labeling management [11][13] Current Market Status - The market is characterized by three main segments: dermatological skincare, high-efficacy skincare, and medical-grade skincare [14] - Consumers are increasingly focused on product efficacy, safety, and ingredient transparency, particularly for sensitive skin [15][16] Sales Channels - Online sales channels dominate the market, with companies like Proya achieving significant revenue from e-commerce [20] - The sales strategy often includes a combination of online and offline channels to maximize reach [19] Profitability - The gross profit margins for most listed companies in the functional skincare sector exceed 70%, with some companies like Jinbo Biological reaching 92.02% due to their focus on medical devices [24] Market Size and Growth - The functional skincare market in China has grown from 10.25 billion yuan in 2017 to an estimated 48.743 billion yuan in 2024 [25][28] - The market is expected to reach 86 billion yuan by 2030, with a compound annual growth rate of approximately 9.0% [33] Competitive Landscape - The competitive landscape is led by companies like Betaini, which holds an 11.71% market share, followed by Huaxi Biological and others [31] - The industry is concentrated in coastal regions, particularly Shanghai and Guangdong [28] Future Trends - The penetration rate of functional skincare products is expected to increase, with a focus on product innovation and medical endorsements [35] - The industry is likely to see intensified competition as consumer preferences evolve towards more personalized and effective solutions [33]

Industry Overview - Neck cream is a skincare product specifically designed for neck care, aiming to nourish, moisturize, and firm the skin, thereby improving its condition and delaying aging signs [2][3] - The neck cream market in China is projected to reach a retail value of 435.7 billion yuan by 2024 [3] Industry Chain - The upstream consists of raw material suppliers, including moisturizing agents, emulsifiers, thickeners, and functional ingredients like hyaluronic acid and peptides. Domestic companies like Huaxi Biological and Zhejiang Peptide Bio are notable suppliers [4] - The midstream includes manufacturers, with international brands like Clarins and Sisley dominating the high-end market, while domestic brands focus on cost-effectiveness and local innovation [4] - The downstream involves sales channels, both online and offline, with social media platforms enhancing product visibility and consumer engagement [5] Current Market Status - The neck cream market is experiencing growth as traditional facial skincare markets slow down, with a market size expected to reach approximately 2.091 billion yuan by 2024 [6][8] - The market has seen a compound annual growth rate (CAGR) of 14.84% from 2019 to 2024, with projections to continue growing at a CAGR of 8.97% from 2025 to 2029 [8] Development Trends - Future trends indicate a move towards customized products targeting different age groups and skin types, alongside the integration of online and offline sales strategies [9] - There is an increasing focus on male skincare, with products designed for male-specific skin characteristics expected to emerge [9]

Group 1: Collagen Industry Insights - Collagen is a vital component in the human body, providing strength, flexibility, and structural support to various tissues, including skin and bones [5][6] - The domestic recombinant collagen market is expected to grow significantly, with a projected CAGR of 41.4% from 2023 to 2027, surpassing the growth rate of animal-derived collagen at 27.7% [6][7] - The application of recombinant collagen spans various sectors, including aesthetic medicine, skincare, intimate health, and hair health, with significant market growth anticipated in each area [7][8] Group 2: Investment Recommendations - The report suggests focusing on companies like Jinbo Biological, which leads in recombinant collagen medical products, and Juzi Biological, known for its strong presence in the beauty market [8] - The domestic beauty care market is rapidly evolving, with increasing consumer acceptance of new products and a growing focus on efficacy and core ingredients [8] Group 3: Changan Automobile Company Overview - Changan Automobile reported a wholesale sales volume of 210,600 vehicles in July 2025, reflecting a year-on-year increase of 23.43% [11][12] - The establishment of the China Changan Automobile Group aims to enhance the integration of the industry chain and promote the development of new energy vehicles [13] - The company plans to launch over 50 global new energy products in the next five years, indicating a strong commitment to innovation and market expansion [13][14]

Group 1: Consumer Services - The report highlights the importance of expanding domestic demand as a key driver for economic growth amid uncertain macroeconomic conditions, with expectations for supportive policies [1] - In Q3, the tourism sector is expected to perform well due to low base effects and the peak travel season, with recommendations for stocks like Changbai Mountain, Nanjing Commercial Travel, and Jiuhua Tourism [1] - The education sector shows stable growth potential, particularly for K12 companies like Xueda Education and AI-focused companies like Doushen Education [1] Group 2: Beauty and Personal Care - The medical beauty sector is undergoing changes due to the emergence of new institutions, with a recommendation to focus on Aimeike as the industry gains attention [2] - Q3 is traditionally a slow season for cosmetics, but opportunities exist for companies with clear catalysts in the second half of the year, including Shangmei Co., Mao Ge Ping, and Ruan Ben Co. [2] - The childcare subsidy policy is expected to benefit companies like Shangmei Co. and Shanghai Jahwa [2] Group 3: Pet Industry - The pet food sector, particularly staple foods, shows strong resilience and performance, while health products and pet supplies are experiencing rapid growth [3] - Domestic brands are expanding overseas and have established production capabilities, making external risks relatively controllable [3] Group 4: Duty-Free - The duty-free sector in Hainan is seeing a narrowing decline in sales, with stable growth in visitor traffic and the gradual opening of city duty-free stores expected to bring additional revenue [4] - The sector's funding structure is favorable, and the fundamentals are at a bottoming stage, with ongoing policy optimizations [4] Group 5: Traditional Retail - The new childcare subsidy policy is expected to positively impact maternal and infant retail companies like Aiyingshi and Kidswant, with more local policies anticipated [5] - Yonghui Supermarket has opened 23 "fat reform" stores, and attention is recommended on the progress and effectiveness of these openings [5] - The average price for toy and beauty care shops in the Small Commodity City has exceeded 130,000, indicating a higher market expectation for future pricing [5] Group 6: Gold and Jewelry - New gold and jewelry companies are focusing on product development and consumer preference analysis through digital systems and social media platforms [6] - As the consumer attributes of gold jewelry companies increase, their valuation systems are expected to shift towards consumer product PEG valuations [6] - The sector is anticipated to perform well in Q3, with recent data indicating a recovery in terminal demand for gold jewelry [6]

Group 1: Collagen Industry Insights - Collagen is a vital component in the human body, providing strength, flexibility, and structural support to various tissues, with low immunogenicity and good biocompatibility [6][7] - The domestic recombinant collagen market is expected to grow significantly, with a projected CAGR of 41.4% from 2023 to 2027, surpassing the growth of animal-derived collagen at 27.7% [7][8] - The application of recombinant collagen spans various sectors, including medical aesthetics, skincare, intimate health, and hair health, with substantial market growth anticipated in these areas [8][9] Group 2: Chang'an Automobile Overview - Chang'an Automobile reported a wholesale sales volume of 210,600 vehicles in July 2025, reflecting a year-on-year increase of 23.43% [12][13] - The establishment of the China Chang'an Automobile Group aims to enhance the integration of the industry chain and promote the development of over 50 global new energy products in the next five years [14][15] - The company is expected to see a significant increase in net profit from 8.448 billion yuan in 2025 to 13.531 billion yuan by 2027, indicating a strong growth trajectory [15] Group 3: Yingzi Network Performance - Yingzi Network achieved a revenue of 2.827 billion yuan in the first half of 2025, marking a year-on-year increase of 9.45%, with a net profit of 302 million yuan [16][17] - The company maintains a leading position in the smart home camera market, with a revenue of 1.548 billion yuan from this segment in the first half of 2025 [16][17] - The overseas revenue accounted for 37.64% of total revenue, reflecting a year-on-year growth of 25.42%, indicating successful international expansion [18] Group 4: Chemical Industry Trends - The Chinese government is focusing on reducing "involution" in market competition, which may lead to structural optimization in the chemical supply side [21][25] - The semiconductor and robotics sectors are experiencing strong demand, with significant growth expected in the AI and new materials fields [22][30] - The chemical industry is anticipated to benefit from domestic production capabilities, with a focus on high-end materials and technology-driven growth [25][26]

港股方面，今年以来吸引力回升，位列第三名，仅次于美股和欧洲市场，但绝对数值相差较大。1-7月 韩国资金净买入5.2亿美元，结束了2022-2024连续3年的资金净卖出。但6、7月整体呈现净卖出，流出 0.78亿美元。 东方财富首席策略官陈果分析表示，25年1-7月，韩国净买入美股140亿美元，欧洲市场74.5亿美元，港 股5.2亿美元，A股-0.5亿美元。6月中下旬港汇处于"弱方兑换保证"以来，港股对韩国投资者的吸引力边 际下降，韩国对港股的净买入转为卖出，6-7月累计净卖出7800万美元。 美股方面，韩国最大净流入权益资产，净买入占比高达99.79%。分月份看，5、6月美股净买入转负， 共净卖出15.4亿美元，7月净买入再次转正，净买入6.9亿美元。 科技板块受到追捧。1-7月，前5大净流入标的中，科技板块占据3个席位。其中，特斯拉及两倍看多位 居净买入前2位，共计净买入37.72亿美元，占对美股投资的31%。此外，区块链公司Circle Internet占据 净买入的第4名。 ETF吸引力高。1-7月，在前10大净流入标的中，有5个ETF；而在50大资金净流入标的中，ETF有19 个。这些ETF共计净买入 ...

Investment Rating - The report suggests a focus on companies in the recombinant collagen sector, highlighting their potential for growth and market leadership [5][6]. Core Insights - Collagen is essential for human health, providing structural support and biological functions [11][14]. - The domestic recombinant collagen technology is advanced, with a complete industrial chain and supportive policies driving growth [6][31]. - The market for recombinant collagen is expected to grow significantly, with a projected CAGR of 41.4% from 2023 to 2027, surpassing the growth of animal-derived collagen [6][27]. - The applications of collagen are diverse, including medical aesthetics, skincare, intimate health, and hair health [6][33]. Summary by Sections 1. Collagen as a Vital Component - Collagen constitutes 30%-40% of human protein and is crucial for skin, bones, tendons, and ligaments [11][14]. - There are at least 29 types of collagen in the human body, with types I and III being the most common in the skin [14][15]. 2. Production: Recombinant vs. Animal-Derived Collagen - Recombinant collagen is produced using gene engineering, offering advantages such as no virus risk and better biocompatibility compared to animal-derived collagen [19][26]. - The market for recombinant collagen is expected to reach 286.3 billion yuan in 2023, with a significant growth trajectory [27][28]. 3. Policy Support for Market Development - The regulatory framework for recombinant collagen has been improving, with various guidelines issued since 2021 to standardize the industry [31][32]. 4. Diverse Applications of Recombinant Collagen - **Medical Aesthetics**: The market for recombinant collagen in medical aesthetics is projected to grow from 43 billion yuan in 2023 to 143 billion yuan by 2027, with a CAGR of 35.4% [6][42]. - **Skincare**: The market for functional skincare products containing recombinant collagen is expected to grow from 115 billion yuan in 2023 to 665 billion yuan by 2027, with a CAGR of 54.9% [47][49]. - **Intimate Health**: The market for intimate health products is anticipated to grow significantly, driven by increasing consumer awareness and demand [51][52]. 5. Key Companies in the Industry - **Jinbo Biological**: A leader in recombinant collagen with unique medical aesthetic products [5][40]. - **Juzi Biological**: Known for its brands Kefu Mei and Keli Jin, actively expanding its medical aesthetic pipeline [5][40]. - **Marubi Biological**: Accelerating its research in collagen, with significant product launches [5][40].

本报讯(记者刘钊)《证券日报》记者从中康数字科技有限公司(以下简称"中康科技")了解到，第十八届 西普会(健康产业生态大会)即将于8月16日至8月21日在海南博鳌举行。本届西普会以"快蜕变，穿越新 周期增长元动力重构与产业生态进化"为主题，旨在探讨健康产业在新周期下的发展趋势。会议将围绕 政策深化、科技创新、市场需求等关键议题展开讨论，并发布《新周期展望》《健康产业未来格局》等 行业报告，为行业发展提供趋势预判。 西普会由中康科技主办，自2008年创办以来，已成为中国健康产业的重要交流平台。本届会议将进一步 促进产业链各环节的协同合作，助力行业应对新周期挑战。 人工智能在健康产业的应用成为本届大会的亮点之一。"AI For Health高峰论坛"将连续举办三天，围 绕"超级个体赋能"与"前沿组织进化"两大主题展开讨论。会上将分享同济医院急诊科AI指挥官应用、云 南白药（000538）AI创新研发实践、互联网产品人机交互专家利用AI零代码编程助力代际健康守护等 实际案例，深入探讨人工智能在医药营销、临床决策、患者管理及企业组织形态重塑等方面的应用前 景。 在产业链协同方面，大会将搭建工业、零售与资本的深度交流平 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 巨子生物控股有限公司 呈交日期: 2025年8月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02367 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | 本月底法定/註冊股本總額 ...